Sign in
4/A

Changes in Ownership

SAB Biotherapeutics, Inc. Filed Acc 0001493152-21-029889

Options or other derivatives

  • Chief Science Officer acquired 294,200 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Bausch Christoph Lawrence · Chief Science Officer

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2021-10-22 Grant or award : show line 1 in the form Employee Stock Option (right to buy) +104,689 104,689 D
2021-10-22 Grant or award : show line 2 in the form Employee Stock Option (right to buy) +81,425 81,425 D
2021-10-22 Grant or award : show line 3 in the form Earnout Rights (Restricted Stock Units) +108,086 108,086 D
Loading xslF345X03/ownership.xml…